Home

About

Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network
FAQHELPSITE MAPCONTACT US


  Advanced Search  

 
DOTA-D-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and
 

Summary: DOTA-D-Tyr1-Octreotate: A Somatostatin Analogue for Labeling
with Metal and Halogen Radionuclides for Cancer Imaging and
Therapy
Wen Ping Li,
Jason S. Lewis,
Joonyoung Kim,
Joseph E. Bugaj,
Michael A. Johnson,
Jack L. Erion,
and Carolyn J. Anderson*,
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110 and
Mallinckrodt, Inc. 675 McDonnell Blvd., St. Louis, Missouri 63134. Received December 10, 2001;
Revised Manuscript Received April 25, 2002
The goal of this study was to evaluate a somatostatin receptor ligand, DOTA-D-Tyr1
-octreotate (DOTA-
DY1-TATE), that has the chelator 1,4,7,10-tetraazacyclotetradecane-N,N,N,N-tetraacetic acid
(DOTA) attached to the D-Tyr1
residue, allowing radiolabeling with both radiohalogens and radiometals.
A potential advantage of having a chelator attached to the Tyr1 residue is that halogen radiolabels
may residualize or remain trapped in tumor cells rather than clear from the tumor. DOTA-DY1-

  

Source: Anderson, Carolyn J. - Department of Molecular Biology and Pharmacology, Washington University in St. Louis

 

Collections: Biology and Medicine